Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL006
MIFTS: 32

Childhood Oligodendroglioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Childhood Oligodendroglioma

About this section

MalaCards integrated aliases for Childhood Oligodendroglioma:

Name: Childhood Oligodendroglioma 12 15
Oligodendroglioma, Childhood 71
Pediatric Oligodendroglioma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Bone diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3183
MeSH 44 D009837
NCIt 50 C4045
UMLS 71 C0280475
Sources

Summaries for Childhood Oligodendroglioma

About this section
MalaCards based summary : Childhood Oligodendroglioma, also known as oligodendroglioma, childhood, is related to anaplastic oligodendroglioma and oligodendroglioma, and has symptoms including seizures and headache. An important gene associated with Childhood Oligodendroglioma is KIAA1549 (KIAA1549), and among its related pathways/superpathways are Cell cycle_Chromosome condensation in prometaphase and Central carbon metabolism in cancer. The drugs Vincristine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include liver.

Sources

Related Diseases for Childhood Oligodendroglioma

About this section

Diseases related to Childhood Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 anaplastic oligodendroglioma 29.5 OLIG2 MGMT IDH2
2 oligodendroglioma 28.6 OLIG2 MGMT IDH2 IDH1 FUBP1 FGFR1
3 adult oligodendroglioma 27.8 OLIG2 MYBL1 KIAA1549 IDH2 IDH1 H3-3B
4 pediatric meningioma 10.3 KIAA1549 FUBP1
5 pilocytic astrocytoma of cerebellum 10.3 KIAA1549 IDH1
6 cerebellar astrocytoma 10.3 KIAA1549 IDH1
7 cerebellum cancer 10.2 KIAA1549 IDH1
8 juvenile astrocytoma 10.2 KIAA1549 IDH1
9 thalamic neoplasm 10.2 MYBL1 KIAA1549
10 high-grade astrocytoma 10.2 IDH1 ATRX
11 benign ependymoma 10.2 KIAA1549 IDH1
12 bone giant cell sarcoma 10.2 H3-3B H3-3A
13 malignant giant cell tumor 10.2 H3-3B H3-3A
14 telangiectatic osteogenic sarcoma 10.2 H3-3B H3-3A
15 enchondroma 10.2 IDH2 IDH1
16 frontal lobe neoplasm 10.2 MGMT IDH1
17 diencephalic neoplasm 10.2 MYBL1 KIAA1549
18 cytogenetically normal acute myeloid leukemia 10.1 IDH2 IDH1
19 colon leiomyoma 10.1 H3-3B H3-3A
20 intracranial chondrosarcoma 10.1 IDH2 IDH1
21 periosteal chondrosarcoma 10.1 IDH2 IDH1
22 optic nerve neoplasm 10.1 OLIG2 KIAA1549
23 juxtacortical chondroma 10.1 IDH2 IDH1
24 bone benign neoplasm 10.1 H3-3B H3-3A
25 bone giant cell tumor 10.1 H3-3B H3-3A
26 spindle cell hemangioma 10.1 IDH2 IDH1
27 supratentorial primitive neuroectodermal tumor 10.1 OLIG2 IDH1
28 oligoastrocytoma 10.1 MGMT IDH2
29 gliofibroma 10.1 MGMT KIAA1549 IDH1
30 brain stem cancer 10.1 IDH1 H3-3B H3-3A
31 alpha thalassemia-x-linked intellectual disability syndrome 10.0 H3-3B H3-3A ATRX
32 d-2-hydroxyglutaric aciduria 1 10.0 IDH2 IDH1
33 bone osteosarcoma 10.0 H3-3B H3-3A ATRX
34 2-hydroxyglutaric aciduria 10.0 IDH2 IDH1
35 gemistocytic astrocytoma 10.0 IDH2 IDH1 ATRX
36 l-2-hydroxyglutaric aciduria 10.0 IDH2 IDH1
37 enchondromatosis, multiple, ollier type 10.0 IDH2 IDH1 ATRX
38 li-fraumeni syndrome 9.9 IDH2 IDH1 ATRX
39 childhood pilocytic astrocytoma 9.9 KIAA1549 IDH1 H3-3B H3-3A
40 juvenile pilocytic astrocytoma 9.9 KIAA1549 IDH1 H3-3B H3-3A
41 clear cell chondrosarcoma 9.9 IDH2 H3-3B H3-3A
42 spinal cord glioma 9.9 KIAA1549 IDH1 H3-3B H3-3A
43 spinal cancer 9.9 KIAA1549 IDH1 H3-3B H3-3A
44 benign giant cell tumor 9.9 H3-3B H3-3A
45 low grade glioma 9.9 MGMT IDH2 IDH1
46 glioma susceptibility 1 9.9 IDH2 IDH1 H3-3A
47 childhood brain stem glioma 9.9 IDH1 H3-3B H3-3A ATRX
48 temporal lobe neoplasm 9.9 MGMT IDH1 FUBP1 ATRX
49 alpha-thalassemia 9.9 IDH1 H3-3B H3-3A ATRX
50 chondroblastoma 9.9 H3-3B H3-3A FGFR1

Graphical network of the top 20 diseases related to Childhood Oligodendroglioma:



Diseases related to Childhood Oligodendroglioma
Sources

Symptoms & Phenotypes for Childhood Oligodendroglioma

About this section

UMLS symptoms related to Childhood Oligodendroglioma:


seizures, headache
Sources

Drugs & Therapeutics for Childhood Oligodendroglioma

About this section

Drugs for Childhood Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
12 Antirheumatic Agents Phase 3
13 Tubulin Modulators Phase 3
14 Antimitotic Agents Phase 3
15 Dermatologic Agents Phase 3
16 Immunosuppressive Agents Phase 3
17 Vitamin B Complex Phase 3
18 Folic Acid Antagonists Phase 3
19 Antimetabolites Phase 3
20 Vitamin B9 Phase 3
21 Folate Phase 3
22 Emetics Phase 3
23 Antiemetics Phase 3
24
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
25
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
26
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
27
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
28
Cyproheptadine Approved Phase 2 129-03-3 2913
29
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Sodium citrate Approved, Investigational Phase 2 68-04-2
32
Tamoxifen Approved Phase 2 10540-29-1 2733526
33
Acetaminophen Approved Phase 2 103-90-2 1983
34
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
35
Iodine Approved, Investigational Phase 2 7553-56-2 807
36
Promethazine Approved, Investigational Phase 2 60-87-7 4927
37
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
38
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
39
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
40
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
41
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
42
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
43 Molgramostim Investigational Phase 2 99283-10-0
44
Cadexomer iodine Experimental Phase 2 94820-09-4
45 Central Nervous System Stimulants Phase 2
46 Contraceptives, Oral Phase 2
47
Megestrol Phase 2 3562-63-8 19090 3080587
48 Contraceptive Agents Phase 2
49 Neurotransmitter Agents Phase 2
50 Histamine H1 Antagonists Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
4 Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
5 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
6 A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas Completed NCT00238264 Phase 2
7 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
8 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
9 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
10 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
11 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
12 A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma Completed NCT00124657 Phase 1, Phase 2 Erlotinib hydrochloride
13 Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide Completed NCT00004068 Phase 2 irinotecan hydrochloride;temozolomide
14 PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS Completed NCT00002749 Phase 2 carboplatin
15 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
16 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
17 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
18 A Phase I/II Study Of A Recombinant Chimeric Protein Composed Of Transforming Growth Factor (TGF)-a And A Mutated Pseudomonas Exotoxin Termed PE38 (TP-38) In Pediatric Patients With Recurrent Or Progressive Supratentorial High Grade Gliomas Terminated NCT00074334 Phase 1, Phase 2
19 Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
20 A Phase I Study of Vinblastine in Combination With Carboplatin for Children With Newly Diagnosed and Recurrent Low-Grade Gliomas Completed NCT00352495 Phase 1 carboplatin;vinblastine sulfate
21 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
22 TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY Completed NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
23 A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
24 A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
25 Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias Completed NCT00030108 Phase 1 ixabepilone
26 Phase I Trial and Pharmacokinetic Study of Temozolomide and O6-Benzylguanine in Childhood Solid Tumors Completed NCT00020150 Phase 1 O6-benzylguanine;temozolomide
27 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
28 Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis Completed NCT00006246 Phase 1 busulfan
29 A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
30 Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients Completed NCT00107185 Phase 1
31 Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
32 Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
33 A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Peripheral Blood Cells With O6-Methylguanine DNA Methyltransferase Completed NCT00005796 Phase 1 lomustine;procarbazine hydrochloride;vincristine sulfate
34 A Trial of 06-BG and BCNU in Children With CNS Tumors Completed NCT00003765 Phase 1 O6-benzylguanine;carmustine
35 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
36 A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors Terminated NCT00006247 Phase 1 semaxanib
37 A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies Terminated NCT00572182 Phase 1 MK-0752
38 Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
39 A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis Terminated NCT00112619 Phase 1 topotecan hydrochloride
40 Efficacy of Gelclairâ„¢ in Reducing the Pain of Oral Mucositis in Children and Young People With Cancer (SC 2005 07) Unknown status NCT00349024 polyvinylpyrrolidone-sodium hyaluronate gel
41 Translation Study for Children and Adolescents With Low Grade Glioma Unknown status NCT00891722
42 Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma Completed NCT00276640 vincristine, carboplatin;vincristine, carboplatin, etoposide
43 Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment Completed NCT00002485
44 A Pilot Study Using Carboplatin, Vincristine And Temozolomide For Children ≤ 10 Years With Progressive/Symptomatic Low-Grade Gliomas Completed NCT00077207 carboplatin;temozolomide;vincristine sulfate
45 Diagnostic and Prognostic Markers in Low-Grade Gliomas Completed NCT01004523
46 Metabolic Syndrome in Childhood Cancer Survivors Completed NCT00920738
47 A Pharmacokinetic Participation Questionnaire Study Completed NCT00890435

Search NIH Clinical Center for Childhood Oligodendroglioma

Sources

Genetic Tests for Childhood Oligodendroglioma

About this section
Sources

Anatomical Context for Childhood Oligodendroglioma

About this section

MalaCards organs/tissues related to Childhood Oligodendroglioma:

40
Liver
Sources

Publications for Childhood Oligodendroglioma

About this section

Articles related to Childhood Oligodendroglioma:

# Title Authors PMID Year
1
Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation. 61
29192869 2018
2
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. 61
29131101 2018
3
Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. 61
26206478 2016
4
Conventional and advanced (DTI/SWI) neuroimaging findings in pediatric oligodendroglioma. 61
25813856 2015
5
Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. 61
24387276 2014
6
Well-differentiated pediatric glial neoplasms with features of oligodendroglioma, angiocentric glioma and dysembryoplastic neuroepithelial tumors: a morphological diagnostic challenge. 61
24448703 2014
7
Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. 61
22941225 2012
8
Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. 61
19934553 2009
Sources

Variations for Childhood Oligodendroglioma

About this section
Sources

Expression for Childhood Oligodendroglioma

About this section
Search GEO for disease gene expression data for Childhood Oligodendroglioma.
Sources

Pathways for Childhood Oligodendroglioma

About this section

Pathways related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cell cycle_Chromosome condensation in prometaphase 23
10.67 H3-3B H3-3A
2
Central carbon metabolism in cancer 36
10.64 IDH2 IDH1 FGFR1
3
Cytosine methylation 1
Show member pathways
 10.07 IDH2 IDH1
Sources

GO Terms for Childhood Oligodendroglioma

About this section

Cellular components related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.56 H3-3B H3-3A CENPM ATRX
2 chromosome, telomeric region GO:0000781 9.33 H3-3B H3-3A ATRX
3 Barr body GO:0001740 8.96 H3-3B H3-3A
4 nuclear chromosome GO:0000228 8.8 H3-3B H3-3A ATRX

Biological processes related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 nucleosome assembly GO:0006334 9.65 H3-3B H3-3A ATRX
2 multicellular organism growth GO:0035264 9.61 H3-3B H3-3A ATRX
3 oogenesis GO:0048477 9.58 H3-3B H3-3A
4 embryo implantation GO:0007566 9.58 H3-3B H3-3A
5 chromatin silencing at rDNA GO:0000183 9.57 H3-3B H3-3A
6 tricarboxylic acid cycle GO:0006099 9.56 IDH2 IDH1
7 nucleus organization GO:0006997 9.55 H3-3B H3-3A
8 telomere organization GO:0032200 9.54 H3-3B H3-3A
9 DNA methylation GO:0006306 9.52 MGMT ATRX
10 muscle cell differentiation GO:0042692 9.51 H3-3B H3-3A
11 2-oxoglutarate metabolic process GO:0006103 9.49 IDH2 IDH1
12 NADP metabolic process GO:0006739 9.46 IDH2 IDH1
13 isocitrate metabolic process GO:0006102 9.4 IDH2 IDH1
14 pericentric heterochromatin assembly GO:0031508 9.37 H3-3B H3-3A
15 regulation of centromere complex assembly GO:0090230 9.32 H3-3B H3-3A
16 negative regulation of chromosome condensation GO:1902340 9.26 H3-3B H3-3A
17 telomeric heterochromatin assembly GO:0031509 9.16 H3-3B H3-3A
18 glyoxylate cycle GO:0006097 8.96 IDH2 IDH1
19 DNA replication-independent nucleosome assembly GO:0006336 8.8 H3-3B H3-3A ATRX

Molecular functions related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.7 OLIG2 MYBL1 MGMT H3-3B H3-3A FUBP1
2 nucleosomal DNA binding GO:0031492 9.37 H3-3B H3-3A
3 NAD binding GO:0051287 9.32 IDH2 IDH1
4 RNA polymerase II core promoter sequence-specific DNA binding GO:0000979 9.26 H3-3B H3-3A
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
6 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1
Sources

Sources for Childhood Oligodendroglioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....